- Home
- MTR vs INDP Comparison
MTR vs INDP Comparison
Compare MTR & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTR
- INDP
- Stock Information
- Founded
- MTR 1979
- INDP 2000
- Country
- MTR United States
- INDP United States
- Employees
- MTR N/A
- INDP N/A
- Industry
- MTR Oil & Gas Production
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- MTR Energy
- INDP Health Care
- Exchange
- MTR Nasdaq
- INDP Nasdaq
- Market Cap
- MTR 11.8M
- INDP 10.2M
- IPO Year
- MTR N/A
- INDP N/A
- Fundamental
- Price
- MTR $6.33
- INDP $0.94
- Analyst Decision
- MTR
- INDP Strong Buy
- Analyst Count
- MTR 0
- INDP 2
- Target Price
- MTR N/A
- INDP $8.50
- AVG Volume (30 Days)
- MTR 14.1K
- INDP 24.7K
- Earning Date
- MTR 01-01-0001
- INDP 11-12-2024
- Dividend Yield
- MTR 3.56%
- INDP N/A
- EPS Growth
- MTR N/A
- INDP N/A
- EPS
- MTR 0.35
- INDP N/A
- Revenue
- MTR $966,169.00
- INDP N/A
- Revenue This Year
- MTR N/A
- INDP N/A
- Revenue Next Year
- MTR N/A
- INDP N/A
- P/E Ratio
- MTR $18.20
- INDP N/A
- Revenue Growth
- MTR N/A
- INDP N/A
- 52 Week Low
- MTR $5.60
- INDP $0.84
- 52 Week High
- MTR $14.49
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- MTR 43.26
- INDP 34.68
- Support Level
- MTR $6.06
- INDP $0.94
- Resistance Level
- MTR $6.79
- INDP $1.06
- Average True Range (ATR)
- MTR 0.31
- INDP 0.05
- MACD
- MTR -0.10
- INDP 0.00
- Stochastic Oscillator
- MTR 20.77
- INDP 0.00
About MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.